Sglt2 Inhibitors Have Heart Benefits For Type 2 Diabetes Patients | Latest News RSS feed

Sglt2 Inhibitors Have Heart Benefits For Type 2 Diabetes Patients - Latest News


Pumps, Pipes, and Filters: SGLT2 Inhibitors for Most Type 2 Diabetes?

Sodium-glucose cotransporter type 2 (SGLT2) inhibitors should be considered for use in most patients with type 2 diabetes ... inhibitors have their greatest and most consistent effect on reducing the ... read more

SGLT2 Inhibitors Work in Type 2 Diabetes Across Levels of CV Risk, Renal Function

Two sodium glucose co-transporter 2 (SGLT2) inhibitors have beneficial effects in patients with type 2 diabetes regardless ... for heart failure individually did not vary by renal function. There ... read more

SGLT2 Inhibitors May Reduce CV, Renal Risks in Type 2 Diabetes

SGLT2i reduced the risks for progression of renal disease by 45% and heart failure hospitalization by 31% in patients ... et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular ... read more

Looking for another news?


Value of SGLT-2 Inhibitors in Type 2 Diabetes

One of the biggest benefits of using an SGLT-2 inhibitor is that it hits a core defect when we look at the different defects that are responsible before hypoglycemia in a patient with type 2 diabetes ... read more


SGLT2 inhibitors: an emerging option for cardiologists?

With studies showing potential for SGLT2 inhibitors in heart failure ... consider the class-wide impact of the cardiovascular benefits of SGLT2 inhibitors, launching a study of type 2 diabetes ... read more

FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes

In addition, empagliflozin is approved to lower the risk of death from heart attack and stroke in adults with type 2 diabetes ... to have the same risk for this rare and serious infection as other ... read more

Certain SGLT2 Inhibitors, GLP-1 RAs for T2DM Also Cut CV Risk

... glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 receptor agonists (GLP-1 RAs) demonstrate significant cardiovascular (CV) benefit and should be used for reducing CV risk in ... read more

SGLT2 Inhibitors are Associated with Reduced Cardiovascular Disease for Patients with Type 2 Diabetes

known as sodium-glucose transporter-2 (SGLT2) inhibitors, is associated with lower rates of death and hospitalization for heart failure when used to treat patients with type 2 diabetes, both with or ... read more

SGLT2 inhibitors may lower risk for HF in patients with type 2 diabetes

The majority of the cohort (87%) did not have established CVD. Those taking SGLT2 inhibitors ... the observed [CV] benefits appear to be class-related. Second, we looked at the broad population of ... read more

SGLT2 inhibitors offer hope for managing heart failure in diabetes

There is a strong connection between heart failure (HF) and diabetes, as 25—44% of patients with HF also have diabetes ... that the CV benefits associated with SGLT2 inhibitors may extend to a broad ... read more

New data from landmark CVD-REAL study of patients with type-2 diabetes confirms CV benefits associated with SGLT-2 inhibitors

Real-world evidence study of more than 400,000 patients with type-2 diabetes, 74% of whom did not have a history of established ... Lower risk of heart failure and death in patients initiated on ... read more

SGLT2 Inhibitors are Associated with Reduced Cardiovascular Disease for Patients with Type 2 Diabetes

The CVD-REAL study analyzed the outcomes of 306,156 patients with type ... that the benefits seen with SGLT2-inhibitors are likely to be a class effect. Previous research has shown that patients with ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us